# Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

> **NCT01802749** · PHASE3 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 406 (actual)

## Conditions studied

- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** pegylated liposomal doxorubicin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01802749
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-11
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802749, "Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01802749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*